Objective. To identify patient-reported outcome (PRO) instruments that assess chronic low back pain (cLBP) symptoms (specifically pain qualities) and/or impacts for potential use in cLBP clinical trials to demonstrate treatment benefit and support labeling claims.
Introduction
Low back pain (LBP) is usually defined as pain, muscle tension, or stiffness localized below the costal margin and above the inferior gluteal folds, with or without leg pain (sciatica). While acute and subacute episodes (lasting up to three months) are the most common presentations of LBP, chronic low back pain (cLBP) causes greater disability (physical limitations and psychological effects) [1] .
Pain has been described as one of the cardinal domains to be assessed in cLBP [2] [3] [4] and is a typical reason for consultation. Pain is one of the best determinants of disability due to LBP [5, 6] and is predictive of work resumption within the year following related short-term absence [7] . Within the biomedical model, the level of pain a patient perceives has been traditionally regarded as a subjective measure. Correlations between self-reported pain and both self-reported disability and objective measures of function are invariably weak [4, 5, 8] , highlighting the need to measure pain in a more direct way. Measurement of pain consistently captures much greater treatment effect sizes than physical variables [5, 9] or condition-specific instruments [10] . Subjective patient assessment of pain and physical limitations due to pain are essential end points for clinical studies.
Patient-reported outcome (PRO) instruments can be used to support claims in medical product labeling where subjective assessments from the patient are important to assessing treatment benefit. The US Food and Drug Administration (FDA) has published a guidance for industry on the development and validation of PRO measures that outlines the evidentiary support needed by the FDA to review a measure for its adequacy to support labeling claims [11] . When reviewing a PRO instrument, the FDA considers the PRO instrument's conceptual framework and its measurement properties (including content validity, reliability, construct validity, and ability to detect change). The guidance also emphasizes the need for adequate documentation of patient input to support the content validity of PRO instruments to be used in evaluating medical outcomes, specifically ensuring comprehensibility is vital to ensure reliable and valid data collection and establish the end point(s) as fit for purpose [11] .
Several questionnaires have been designed to measure cLBP symptoms and symptom-related impacts, but their validity and symptom comprehensiveness may not fully satisfy the FDA guidance for PRO instruments to support claims in approved medical product labeling. Although the FDA has accepted a single patientreported item of worst pain severity for the approval of products for pain conditions in the past, the symptombased characterization of the patient's pain experience with a single item is limited. The objective of this review was to summarize key characteristics of a selection of existing instruments that assess cLBP symptoms and/or impacts to determine which have the strongest measurement properties for potential use in cLBP clinical trials. This search and instrument review was conducted to support early decision-making about appropriate measures to consider for use in therapeutic clinical trials by two pharmaceutical companies.
Methods

Selection of Candidate Instruments
The goal of this review of PRO instruments was to identify those that have the best measurement properties, provide the best coverage of the selected concepts (LBP symptoms and impacts), provide the best fit for clinical study design and measurement strategy to support a label claim that has been used in LBP studies, and offer any other additional benefits. To be selected for review, instruments were in English, were cLBPspecific or had been used in cLBP clinical trials, and measured the symptoms and/or impacts from cLBP. Generic pain measures were also included for review if the measure had been used in a cLBP clinical trial. Instruments were excluded if they were general instruments (excluding general pain measures) not specific to LBP, were cLBP-specific instruments that did not measure pain symptoms and/or pain impacts, were cited infrequently (fewer than three citations per year since development), were developed prior to the 2009 FDA PRO guidance and did not demonstrate compliance with the guidance, or were not developed or used for cLBP. Other possible measures that were very new but had no published data yet for use in cLBP populations were excluded (i.e., the Patient-Reported Outcome Measurement Information System [PROMIS] pain measures [12] ). The generic PROMIS pain measures were not selected in our review because the measures were not developed for use by patients with cLBP [13] and because item banks were deemed too broad for use in a cLBP trial. Generic quality of life measures were excluded, along with measures that assessed more distal concepts unlikely to be considered end points in clinical trials to support product labeling (e.g., effects on social life or relationships and emotional impacts). Any published previous versions of the existing measures were also excluded.
Systematic Assessment of Selected Instruments
The quality of each selected PRO instrument was assessed in terms of its appropriateness in reflecting patients' perspectives in a given study and context of use, as described by the FDA PRO guidance document [11] . Instruments were evaluated for the following characteristics: name/acronym, general description (purpose, content, versions, number of items), development history (patient involvement, development population, crosscultural input, known use in studies), scoring (response scale, recall period, method of scoring, patient burden, interpretation of scores), measurement properties (reliability, validity, ability to detect change), and an overview of strengths regarding potential use in a phase III clinical trial.
Results
Selected Instruments
A literature search for articles describing PRO measures for cLBP was conducted in 2011 and updated in 2015 using Medline (Figure 1 ). In the 2011 search, a systematic review by Chapman and colleagues [14] was found that identified 16 PRO instruments commonly used to assess cLBP in addition to clinician-based outcomes and physiological outcome measures. Additional instruments were identified in a review of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group recommendations (four instruments) [15] , a search in PROQOLID [16] and ISPOR [17] databases (nine instruments), a parallel literature review on patient perspectives of cLBP (five instruments), and experience by the research team in the conduct of pain clinical trials (five instruments). In the 2015 search, a total of 137 measures and scales were identified in the Medline (PubMed) database. Of all of the PRO instruments identified in both searches, 163 instruments were excluded for relevance (Supplemental Table S1 ) and a total of 13 instruments were included in the final analysis.
The 13 PRO instruments to be evaluated were grouped by domain: 1) symptom descriptions (pain qualities), 2) pain-related impacts, and 3) instruments addressing both symptoms and impacts. The instruments and citations for key publications that describe the development and measurement properties are briefly described below. Table 1 describes the PRO instruments, scoring, and interpretation of scores, and Table 2 summarizes the relevance of each selected measure to cLPB. Measures That Assess Symptom Descriptions (Pain Qualities)
Low Back Pain Bothersomeness Scale
This measure was included in our review because of references turning up in literature, and it was of interest as it was LBP-specific. However, our review did not identify a single, specific low pack pain bothersomeness scale (LBP-BS). Some LBP bothersomeness measures used one item [18] while others included multiple items about specific symptoms [19] . No publication discussed the development of the measure, and none of the varied scales identified were developed using a population specifically with cLBP. Because of the inconsistency of identifiable scales, the overall lack of necessary information, and the difference in the developmental population, we felt the information available on the scale's measurement properties could not be generalized.
Neuropathic Pain Symptom Inventory
The Neuropathic Pain Symptom Inventory (NPSI) was designed to assess the symptoms of neuropathic pain and was derived from the clinical experience of the authors and literature review on pain qualities most often identified by patients with various chronic pain conditions [20] . Measurement properties of the NPSI were determined in patients with neuropathic pain due to peripheral or central injury. Content validity, internal consistency, test-retest reliability, convergent validity, divergent validity, and sensitivity to change with treatment have been documented with the NPSI, but the instrument is not specific to patients with cLBP.
PainDETECT
The PainDETECT (PD-Q) is a screening tool that was developed in Germany to detect neuropathic pain components in cLBP patients [21] [22] [23] [24] [25] [26] . More than 300,000 patients have been assessed with the PD-Q, providing the basis for one of the largest data sets for chronic pain. This instrument has been validated in patients with postherpetic neuralgia, painful polyneuropathy, nerve trauma, LBP, visceral pain, osteoarthritis, inflammatory arthropathies, and mechanical cLBP. There was no patient involvement described in the development of this measure. The measure demonstrated adequate internal consistency, test-retest reliability, and convergent validity, but did not predict treatment response to usual care in cLBP patients. There are no reports of patient burden for this measure or time required to complete the measure. The stability of pain descriptors in the PD-Q has been shown to be accurate for one to three weeks.
Pain Quality Assessment Scale and Revised Pain Quality Assessment Scale (Self-administered)
The Pain Quality Assessment Scale (PQAS) is a questionnaire designed to assess pain qualities associated with both neuropathic and non-neuropathic pain conditions [27] [28] [29] [30] [31] [32] [33] . The instrument was originally validated in patients with carpal tunnel syndrome. No patient involvement was reported in the development of the PQAS, but patient input was sought during the cognitive testing stage. Although the instrument has good content validity, internal consistency, and ability to detect change, it has not been validated for the cLBP population.
Revised Short Form McGill Pain Questionnaire
The long version and the first short version of this questionnaire were developed for the assessment of all types of pain. The Revised Short Form McGill Pain Questionnaire (SF-MPQ-2) was developed to provide a comprehensive measure of pain quality for both neuropathic and non-neuropathic pain conditions [34] . The original instrument was validated in patients with diabetic peripheral neuropathy and has since been validated in populations with diverse chronic pain conditions. The SF-MPQ-2 has demonstrated good content validity, internal consistency, convergent validity, and sensitivity to change, but it needs to be validated in the cLBP population.
Measures that Assess Pain-Related Impacts
Oswestry Disability Index
The Oswestry Disability Index (ODI) was designed to indicate the extent to which a person's functional level is restricted by disability in adults with LBP [35] [36] [37] . The ODI was originally validated in patients with spine conditions, including LBP. The ODI has demonstrated good reliability, test-retest reliability, convergent validity, and responsiveness to change, particularly in patients with chronic pain and severe disability.
Pain Disability Index
The Pain Disability Index (PDI) was designed to measure the extent to which chronic pain interferes with a person's ability to engage in various life activities [38] [39] [40] [41] . The PDI was validated in patients with chronic pain (not specified). The PDI was found to be internally consistent with good convergent validity and was responsive to change, but had variable test-retest reliability and does not have a clear recall period.
Roland-Morris Disability Questionnaire
The Roland-Morris Disability Questionnaire (RMDQ) is a measure that assesses physical disability due to LBP [42] [43] [44] [45] [46] [47] . This instrument was originally validated in patients with LBP. The RMDQ had good internal consistency, test-retest reliability, convergent validity, and was 
Chronic Low Back Pain Impact Questionnaire
The Chronic Low Back Pain Impact Questionnaire (CLBP-IQ) is a new instrument that has been designed to assess the impact of cLBP for use in clinical trials [48] . The CLBP-IQ was developed using input from subjects taking daily analgesic medications for at least three months for their cLBP. Concept elicitation interviews were conducted to gather information about the symptoms and impacts experienced by subjects. Cognitive interviews were conducted to evaluate the clarity and comprehensiveness of the draft instrument items and instructions. No published clinical trials or studies have used the CLBP-IQ. The development article is the only published literature on the CLBP-IQ. This instrument has not been validated in any patient population.
Measures That Assess Symptom Descriptions (Pain Qualities) and Pain-Related Impacts
The Brief Pain Inventory and Brief Pain Inventory Short Form
The Brief Pain Inventory and Brief Pain Inventory Short Form (BPI/BPI-SF) measure the intensity of pain and interference of pain in the patient's life [49] [50] [51] [52] [53] . This instrument has been validated in patients with LBP, but not specifically for patients with cLBP. The BPI showed good internal consistency, test-retest reliability, convergent validity, and sensitivity to change, and discriminated among levels of pain severity.
Musculoskeletal Outcomes Data Evaluation and Management System-Spine Module
The Musculoskeletal Outcomes Data Evaluation and Management System (MODEMS)-Spine Module was originally developed to measure spine-related musculoskeletal diseases and injuries [54] [55] [56] [57] [58] . The MODEMSSpine Module has not been validated in a patient population. There is no available documentation of patient involvement in the development of this measure. There is also no evidence of reliability data or ability to detect change.
Orebro Musculoskeletal Pain Questionnaire
The Orebro Musculoskeletal Pain Questionnaire (OMPQ) was designed as a screening tool for people who have suffered back injuries to determine which patients are at risk of developing persistent back pain or disability and which patients are most in need of early intervention [59] [60] [61] [62] [63] . Measurement properties of the OMPQ have been assessed in patients with acute or subacute back or neck pain, but the instrument has not been validated. The developer does not report any patient involvement in the development of the instrument. The OMPQ has been shown to have good test-retest reliability and ability to detect change, but variable predictive validity.
West Haven-Yale Multidimensional Pain Inventory (Interference Scale)
The West Haven-Yale Multidimensional Pain Inventory (WHYMPI; also known as the MPI) was developed to assess several dimensions of the chronic pain experience and was founded in cognitive-behavioral theory [64] [65] [66] [67] [68] [69] [70] [71] [72] . The WHYMPI has not been validated. Patient involvement during the development process differed for each of three parts of the measure. The WHYMPI was reported to have good internal consistency, test-retest reliability, convergent validity, and ability to detect change.
Discussion
We identified 13 instruments that have the potential to assess key patient-reported concepts surrounding cLBP symptoms and impacts. Several of these instruments have strong psychometric properties, but none of the instruments fulfilled criteria for use in clinical trials to support labeling claims based on FDA PRO guidance. While such evidence might exist in developer's files, our searches were not able to locate published documentation to indicate that this critical step had been conducted during the development process. Ideally, identification or development of an appropriate PRO instrument should be done early in a clinical development program, but our purpose was to evaluate PRO instruments that would be suitable for the purpose of pursuing a label claim, not just to be used in a clinical trial.
PRO instruments can be developed for a specific measurement strategy, or if acceptable candidate instruments can be identified or potentially modified to adequately assess a clinical trial end point, it may be possible to avoid the burden of new instrument development. The FDA requires documentation of several key aspects of a PRO if the goal of the sponsor is to use the PRO for a drug label [11] . Evidence of patient input during the PRO development is important to ensure that the instrument is based on concepts relevant to the patient's experience. When using or modifying an existing instrument and the development history is not available, sponsors should provide documentation of content validity, including open-ended patient input from the appropriate patient population. Seven of the 13 instruments in this review had no documentation of patient involvement, and of the six instruments that did have documented patient input, only three were validated in patients with cLBP.
The PRO developer should also provide documentation supporting the choice of recall period(s). The optimal recall period will depend on the purpose and intended use of the instrument, including the variability, duration, frequency, and intensity of the concept measured, characteristics of the disease, and the treatment [11] . A critical aspect of the recall period is the patient's ability to accurately recall the information requested. Four of the 13 instruments examined had no recall designated, one instrument used various recall periods ranging from weeks to months, three instruments used a recall period of the "past week," and two instruments had a recall period of the last 24 hours.
The PRO developer must also provide documentation supporting the choice of response options. Possible response options for PROs include visual analog scales, Likert scales, rating scales, pictorial scales, checklists, and recording of events as they occur. Response options should be clear and appropriate for the intended population, offer a clear distinction between choices, avoid potential ceiling or floor effects, and avoid bias in the direction of responses [11] . The number of options should be empirically justified [11] . A variety of response options were noted in the PRO instruments reviewed here.
Content validity, reliability, and the ability to detect change are critical elements that are used by the FDA to evaluate an instrument to support potential labeling claims. Content validity, the degree to which the instrument measures the concept of interest, should be supported by qualitative studies to evaluate the items and domains of an instrument in the target population. According to the FDA, content validity should be established before other properties of the instrument can be assessed. Reliability of an instrument (ability to provide consistent, reproducible estimates of a treatment effect) and the ability to detect change are important to document improvement or worsening of PROs in patients participating in clinical trials. Of the instruments reviewed here, most had been tested for these properties, although most were not evaluated in patients with cLBP.
In recognition of the importance of PROs and to support the development of PRO instruments, the Patient-Reported Outcome Measurement Information System was initiated and funded by the National Institutes of Health in 2004 (12) . The goal of PROMIS is to develop universally relevant measures rather than disease-specific measures [13] . The PROMIS system includes four instruments that were potential candidates for further review: pain behavior, pain interference, pain intensity, and physical function mobility questionnaires [73] . These generic measures were not selected in our review because the measures were not developed for use by patients with cLPB and because item banks were deemed too broad for use in a cLBP trial. A suitable measure could be constructed using specific items from the PROMIS item banks; however, such a measure would still need to undergo further testing and validation with cLBP patients. In reviewing the National Institutes of Health Task Force standards for clinicians who treat cLBP, we find that the PROMIS instruments are recommended by the Task Force as useful to collect valuable and meaningful information on the patient experience [74] . As PROs are not a major emphasis of the Task Force report, our findings could potentially supplement the information in the report by providing a summary of how well various PROs assess the symptoms and impacts of cLBP.
This early step in assessing the appropriateness of existing measures is only a first start in the selection process. The steps outlined here need to be completed in order to clarify whether these measures are the most appropriate pathway forward, whether a modification of any of them might be advisable, or if a new measure needs to be developed to address the symptoms and impacts of cLBP from the patient perspective. Any selection or development of a cLBP-specfic measure would need to go through the usual process of being evaluated in early-phase trials prior to use in pivotal studies to support label claims.
In summary, this review describes existing PRO instruments that have the potential to be used for patients with cLPB. None of the instruments reviewed met the FDA's criteria for use in clinical trials of cLBP to support labeling claims, leaving the next step to be decisions on whether an existing measure might be modified or if a new PRO instrument needs to be developed for this purpose. 
